Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Five Prime Therapeutics, Inc.”

67 pharma patents match "Five Prime Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 67
Index total 30,257
Page 3 / 3

Quick answer

This filtered view shows 67 pharmaceutical patents matching "Five Prime Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

67 results for “Five Prime Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 8580936

    Polynucleotides encoding FGFR1-IIIc ECD fusion proteins

    Five Prime Therapeutics, Inc. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted

  2. US 8575312

    Compositions and methods of use for MGD-CSF in disease treatment

    Five Prime Therapeutics, Inc. · Granted Nov 5, 2013 · Expires Oct 31, 2033

    granted

  3. US 8501191

    FGFR2-IIIb fusion proteins and methods of making them

    Five Prime Therapeutics, Inc. · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted

  4. US 8481038

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  5. US 8445445

    Method of promoting hair growth using FGFR4 extracellular domains

    Five Prime Therapeutics, Inc. · Granted May 21, 2013 · Expires May 16, 2033

    granted

  6. US 8431532

    FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same

    Five Prime Therapeutics, Inc. · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  7. US 8404810

    Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma

    Five Prime Therapeutics, Inc. · Granted Mar 26, 2013 · Expires Mar 21, 2033

    granted

  8. US 8338569

    FGFR extracellular domain acidic region muteins

    Five Prime Therapeutics, Inc. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  9. US 8324165

    Compositions for treating arthritis comprising HG1023575 polypeptide

    Five Prime Therapeutics, Inc. · Granted Dec 4, 2012 · Expires Nov 29, 2032

    granted

  10. US 8206715

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Jun 26, 2012 · Expires Jun 21, 2032

    granted

  11. US 8183207

    Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules

    Five Prime Therapeutics, Inc. · Granted May 22, 2012 · Expires May 17, 2032

    granted

  12. US 8178109

    Compositions and methods of use for MGD-CSF in disease treatment

    Five Prime Therapeutics, Inc. · Granted May 15, 2012 · Expires May 10, 2032

    granted

  13. US 8173134

    ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them

    Five Prime Therapeutics, Inc. · Granted May 8, 2012 · Expires May 3, 2032

    granted

  14. US 8168588

    Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions

    Five Prime Therapeutics, Inc. · Granted May 1, 2012 · Expires Apr 26, 2032

    granted

  15. US 8080246

    Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules

    Five Prime Therapeutics, Inc. · Granted Dec 20, 2011 · Expires Dec 15, 2031

    granted

  16. US 8058403

    Antibodies to stromal cell-derived factor-1 polypeptides

    Five Prime Therapeutics, Inc. · Granted Nov 15, 2011 · Expires Nov 10, 2031

    granted

  17. US 7982014

    FGFR3-IIIc fusion proteins

    Five Prime Therapeutics, Inc. · Granted Jul 19, 2011 · Expires Jul 14, 2031

    granted

  18. US 7776564

    Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use

    Five Prime Therapeutics, Inc. · Granted Aug 17, 2010 · Expires Aug 12, 2030

    granted

  19. US 7678890

    Compositions and methods of treating disease with FGFR fusion proteins

    Five Prime Therapeutics, Inc. · Granted Mar 16, 2010 · Expires Mar 11, 2030

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.